Affiliation:
1. From the Department of Medical Oncology, Erasmus MC University Medical Center, Daniel den Hoed Cancer Center; Department of Clinical Chemistry, Erasmus MC University Medical Center, Rotterdam, the Netherlands; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden; and the Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN
Abstract
PurposeSeveral constituents of cigarette smoke are known to interact with drug metabolizing enzymes and potentially affect treatment outcome with substrate drugs. The purpose of this study was to determine the effects of cigarette smoking on the pharmacokinetics and adverse effects of irinotecan.Patients and MethodsA total of 190 patients (49 smokers, 141 nonsmokers) treated with irinotecan (90-minute intravenous administration on a 3-week schedule) were evaluated for pharmacokinetics. Complete toxicity data were available in a subset of 134 patients receiving 350 mg/m2or 600 mg flat-fixed dose irinotecan.ResultsIn smokers, the dose-normalized area under the plasma concentration-time curve of irinotecan was significantly lower (median, 28.7 v 33.9 ng · h/mL/mg; P = .001) compared with nonsmokers. In addition, smokers showed an almost 40% lower exposure to SN-38 (median, 0.54 v 0.87 ng · h/mL/mg; P < .001) and a higher relative extent of glucuronidation of SN-38 into SN-38G (median, 6.6 v 4.5; P = .006). Smokers experienced considerably less hematologic toxicity. In particular, the incidence of grade 3 to 4 neutropenia was 6% in smokers versus 38% in nonsmokers (odds ratio [OR], 0.10; 95% CI, 0.02 to 0.43; P < .001). There was no significant difference in incidence of delayed-onset diarrhea (6% v 15%; OR, 0.34; 95% CI, 0.07 to 1.57; P = .149).ConclusionThis study indicates that smoking significantly lowers both the exposure to irinotecan and treatment-induced neutropenia, indicating a potential risk of treatment failure. Although the underlying mechanism is not entirely clear, modulation of CYP3A and uridine diphosphate glucuronosyltransferase isoform 1A1 may be part of the explanation. The data suggest that additional investigation is warranted to determine whether smokers are at increased risk for treatment failure.
Publisher
American Society of Clinical Oncology (ASCO)
Reference70 articles.
1. Behavior and Cancer Prevention
2. Giovannucci E: An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 10:725,2001-731,
3. Associations Between the Age at Diagnosis and Location of Colorectal Cancer and the Use of Alcohol and Tobacco
4. Spitz MR, Fueger JJ, Eriksen MP, et al: Cigarette smoking patterns of cancer patients. Prog Clin Biol Res 339:73,1990-82,
5. Analysis of Cigarette Smoking Habits of Cancer Patients Referred to the Northeastern Ontario Regional Cancer Centre
Cited by
113 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献